Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody  by Sánchez-Martínez, Silvia et al.
FEBS Letters 580 (2006) 2395–2399Speciﬁc phospholipid recognition by human immunodeﬁciency virus
type-1 neutralizing anti-gp41 2F5 antibody
Silvia Sa´nchez-Martı´neza, Maier Lorizatea, Hermann Katingerb, Renate Kunertb,
Gorka Basan˜eza, Jose´ L. Nievaa,*
a Bioﬁsika Unitatea (CSIC-UPV/EHU) and Biokimika Saila, Euskal Herriko Unibertsitatea, Posta Kutxa 644, 48080 Bilbao, Spain
b Institute of Applied Microbiology, University of Agriculture, A-1190 Vienna, Austria
Received 19 January 2006; revised 16 March 2006; accepted 24 March 2006
Available online 30 March 2006
Edited by Hans-Dieter KlenkAbstract HIV-1 neutralizing monoclonal antibody (Mab) 2F5
recognizes a membrane-partitioning gp41 sequence. Just recently
its capacity to react with cardiolipin has been demonstrated.
Here, we have studied the speciﬁcity of Mab2F5-phospholipid
interactions comparing partitioning into lipid bilayers with rec-
ognition of molecular species dispersed in solution. Using a lipo-
some-based ELISA we demonstrate a preferential association
with cardiolipin bilayers. When diﬀerent soluble lysoderivatives
were compared in their capacity to inhibit Mab2F5 binding to
immobilized HIV-1 peptide epitope, only dilysocardiolipin re-
sulted eﬀective in blocking the process. Dilyso-cardiolipin also
competed with native-functional gp41 for 2F5 recognition. Thus,
our data support speciﬁc cardiolipin recognition by 2F5 that is
not dependent on lipid bilayer assembly and involves the epi-
tope-binding site. These ﬁndings might be of relevance for under-
standing the molecular basis of HIV-1 immune evasion.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Monoclonal antibody (Mab) 2F5, isolated from an asymp-
tomatic human immunodeﬁciency virus type-1 (HIV-1) infected
patient, is one of the few broadly neutralizing anti-HIV-1 anti-
bodies described to date [1–3]. Mab2F5 recognizes ELDKWA
epitope, a sequence contained within the ‘‘aroma’’ or ‘‘mem-
brane-proximal external region’’ (MPER) domain of gp41
envelope subunit [1–5]. This highly conserved stretch preceding
the gp41 transmembrane anchor is predicted to reside immersed
into the membrane-interface [5,6]. Mab2F5 simultaneously
exerts broad and potent neutralizing activity across diﬀerent
HIV-1 strains [7,8] interrupts mucosal transmission and viral
spread and confers protection to viral infection when passively
transferred to primate models (reviewed in [9]). Consequently,Abbreviations: CL, cardiolipin; HIV-1, human immunodeﬁciency virus
type-1; Mab, monoclonal antibody; MPER, membrane-proximal ext-
ernal region; PC, phosphatidylcholine; PG, phosphatidylglycerol; PL,
phospholipid; WW, Wimley–White
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In addition, 2F5 epitope sequence has gathered considerable
interest as a potential lead for vaccine development. However,
diverse epitope-mimicking peptide immunogens have failed to
elicit neutralizing responses with 2F5 speciﬁcity (reviewed in
[11]).
Haynes et al. [12] have recently provided evidence indicating
that Mab2F5 recognizes the phospholipid (PL) cardiolipin
(CL). According to these authors, the fact that anti-CL anti-
bodies are linked to autoimmune diseases in humans raises
the possibility that HIV may have evolved CL-emulating
MPER epitopes as a strategy to evade the immune response.
This would imply a speciﬁc mechanism of CL recognition
involving the epitope-binding site. However, molecular analy-
sis [13] and subsequent crystal structure resolution of antigen-
binding 2F5 fragment [14] revealed the presence of a long
CDR3 loop of heavy chain containing aromatic and other
hydrophobic residues. These amino acids do not establish di-
rect contacts with bound epitopes, raising the possibility that
the CDR3 loop may play a role in promoting the Mab-mem-
brane association required to recognize interfacial gp41 se-
quences [11,14].
In the present work, we use membrane model systems to gain
insights into the speciﬁcity of Mab2F5 interactions with phos-
pholipids. Using a liposome-based ELISA we demonstrate that
Mab2F5 preferentially partitions into CL bilayers. We further
test the speciﬁcity of Mab2F5–PL interactions in absence of
surface phenomena measuring binding to diﬀerent lyso-deriva-
tives including dilysoCL. The latter is subsequently shown to
interfere with Mab2F5 recognition of native-functional gp41
expressed at cell surfaces. These ﬁndings support a Mab2F5-
cardiolipin recognition mechanism that is independent of mem-
brane-partitioning and involves the epitope-binding site.2. Materials and methods
2.1. Materials
NEQELLELDKWASLWNWFNITNWLWYIK (MPER), NE-
QELLELDKWASLWN and ELDKWA epitope sequences were syn-
thesized by solid-phase synthesis using Fmoc chemistry and puriﬁed
by HPLC at the Proteomics Unit of the University Pompeu-Fabra
(Barcelona, Spain). Neutralizing antibody expressing hybridomas were
generated by a combined PEG-electrofusion of peripheral blood mono-
nuclear cells of HIV infected non symptomatic patients [15]. Mab2F5
was produced in recombinant CHO cells after subclass switch to
IgG1 [16]. 1,2-dioleoyl-sn-glycero-3-phosphoetanolamine-N-(biotinyl)
(biot-PE), 1-palmitoyl-2-oleoylphosphatidylcholine (PC), cardiolipinblished by Elsevier B.V. All rights reserved.
Fig. 1. (A) Average hydropathy-at-interface for the CDR3 loop of
heavy chain of Mab2F5. A window of ﬁve amino acids was used with
the hydrophobicity scale at membrane interfaces of Wimley and White
[3,19]. The sequence on top of the positive peak displays favorable
interaction with the membrane-interface. (B) Mab2F5 association with
lipid bilayers as inferred from lipisome-based ELISA. 0.1 mM lipid
vesicles (PL: biotPE 99:1 mol:mol ratio) were immobilized into
streptavidin-coated plaques. The panel displays Mab2F5 association
with immobilized PC (circles), PG (triangles) and CL (squares)
vesicles. Means of duplicate points in representative experiments are
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soPC), oleoyl-lysophosphatidylglycerol (lysoPG) and dilysocardiolipin
(dilysoCL), were purchased from Avanti Polar Lipids (Birmingham,
AL, USA). CHO-Env cell lines (contributed by C. Weiss and J. White)
and HeLa cell lines (contributed by R. Axel) were obtained from the
NIH AIDS Research and Reference Reagent Program (ARRRP).
2.2. Enzyme-linked immunosorbent assay (ELISA)
For liposome-based ELISA protocol, 100 lM phospholipid vesicles
were immobilized on streptavidin-coated wells (Nunc, Denmark). Lip-
osomes, were obtained through sonication of lipids dispersed in buﬀer,
and composed of phospholipid doped with 1 mol% of biot-PE. The
background values were estimated from parallel assays in absence of
Mab-s. Degree of Mab binding was revealed through detection with
alkaline phosphatase-conjugated goat anti-human immunoglobulin
(Pierce, Rockford, IL, USA). Color was subsequently developed with
the substrate p-nitrophenyl phosphate (Sigma, St. Louis, MO, USA),
and absorbance at 405 nm measured in a Synergy HT microplate read-
er (Bio-TEK Instruments Inc., VT, USA). For competition ELISA,
MPER was dissolved in phosphate-buﬀered saline (PBS) and immobi-
lized (100 ll/well) overnight in C96 Maxisorp microplate wells (Nunc,
Denmark) at a concentration of 1 lM. Plates were blocked for 2 h with
3% (w/v) bovine-serum albumin in PBS. Deﬁned volumes of competing
epitopes or lipid vesicles (binding in solution) were incubated for
30 min with Mab prior to addition to the blocked wells.
2.3. Blockade of syncytium inhibition
Antibody binding to native gp41 expressed in cell surfaces was deter-
mined in a syncytium inhibition assay [1]. Syncytium assay was carried
out using CHO-Env cells (ARRRP-NIH, contributed by C. Weiss and
J. White). CHO-WT expressing HIV-1 HXB2 Env, were grown and
assayed according to contributors’ instructions. CHO-WT cells were
co-seeded with HeLaT4+ cells expressing CD4 and CXCR4
(ARRRP-NIH, contributed by R. Axel) and incubated overnight. Syn-
cytia were scored under phase contrast using an Olympus CKX41 in-
verted microscope equipped with a Camedia C-5050 digital camera
(Olympus-Europe, Hamburg, Germany). Syncytium inhibition assay
was performed incubating Mabs for 90 min with CHO-WT cells prior
to coculturing with HeLaT4+ cells. Reversion of the inhibitory eﬀect
was achieved by pre-incubating Mabs with peptides or PL-s for
90 min before addition to CHO-WT cells.displayed in all plots.3. Results and discussion
Mab2F5 recognizes a gp41 sequence predicted to reside at
the membrane interface according to Wimley–White (WW)
hydrophobicity analyses [5,17]. Interfacial aﬃnity plot dis-
played in Fig. 1A identiﬁes a Mab2F5 CDR H3 loop sequence
with the potential to promote partitioning into membrane sur-
faces. Thus, WW analysis also supports the suggestion that
recognition of the membrane-associated epitope by Mab2F5
could be assisted by the long CDR H3 loop [14]. Mab2F5-
membrane association was subsequently tested using a lipo-
some-based ELISA (panel B). Vesicles immobilized in plaques
mimicked the bilayer-interface region that plays a critical role
in the refolding events accompanying protein penetration into
membranes [18]. Results on antibody–liposome binding dis-
played in Fig. 1B indicate that Mab2F5 associated to anionic
diphosphoglycerol interfaces provided by CL vesicles, with
apparent higher aﬃnity than to electrically neutral phospho-
choline interfaces provided by PC vesicles. Non-speciﬁc bind-
ing of proteins to charged membrane interfaces depends
upon the combined contributions of hydrophobic and electro-
static interactions [19]. However, Mab2F5 binding to nega-
tively charged phosphoglycerol interfaces provided by PG
vesicles was lower than to CL and comparable to that mea-
sured in neutral PC vesicles. This indicates that a favorableelectrostatic interaction with negatively charged interfaces
could not account for the observed increase in Mab2F5 aﬃnity
to CL. Thus, while Mab2F5 capacity for partitioning into PC
and PG membrane-interfaces seemed to be mainly based on
unspeciﬁc hydrophobic interactions, additional interactions
could be established with CL.
In order to gain insight into the speciﬁcity of Mab2F5-CL
interaction and probe the involvement of the binding pocket
in the process, binding to PL-s assembled in membrane bilay-
ers and dispersed in solution were comparatively examined in
standard inhibition ELISAs (Fig. 2A). To carry out these as-
says the MPER peptide representing the 656NEQELLELDK-
WASLWNWFNITNWLWYIK683 stretch of gp160 (Gen
Bank Accession No. M15654) was immobilized in the plaques.
Pre-incubation of Mab2F5 with PC vesicles inhibited its inter-
action with MPER (solid lines in left-hand side panel). Under
identical conditions, pre-incubation with CL vesicles inhibited
the interaction between Mab2F5 and MPER even more eﬀec-
tively (center panel). No signiﬁcant inhibition was observed
when Mab2F5 was pre-incubated with lysoPC (dashed lines
in left-hand panel). In contrast, dilysoCL inhibited Mab2F5
binding to immobilized MPER, although less eﬃciently than
CL vesicles (center panel). Interestingly, pre-incubation with
PG vesicles, but not lysoPG, reduced the interaction of
Mab2F5 with MPER. The chemical nature of PG is closely re-
Fig. 2. Phospholipid recognition in solution and membranes. (A) Inhibition of Mab2F5 binding to MPER immobilized in standard plaques by pre-
incubation in solution with lipid bilayers (circles and solid lines) or monomeric lysolipids (squares and dashed lines). Displayed data compare
inhibition exerted by PC and lysoPC (left-hand side panel), CL and dilysoCL (center panel) and PG and lysoPG (right-hand panel). MPER and
Mab2F5 were used in these assays at the concentrations of 5 and 0.1 lg/ml, respectively. Plotted values correspond to means of three independent
experiments ± S.D. (B) Structures of CL and dilysoCL (left) and PG and lysoPG (right) used in the previous experiments. Images kindly provided by
Avanti Polar Lipids, Inc.
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results displayed in Fig. 2 are consistent with the establishment
of speciﬁc interactions with the epitope-binding pocket of
Mab2F5, which seemed to require a polar-head glycerol moi-
ety with ester phosphates at two positions (Fig. 2B).
To further test whether CL functions as a true ligand of
Mab2F5, we analyzed side-by-side the ability of core-epitope
ELDKWA (residues 662–667 of gp160) and dilysoCL to inter-
fere with recognition of: (i) MPER immobilized in plaques
(Fig. 3A), and (ii) native gp41 expressed on cell surfaces
(Fig. 3B). Both ELDKWA and dilysoCL inhibited Mab2F5
adsorption to MPER-coated plaques similarly, although this
inhibition was much less eﬃcient than that induced by the
longer linear 2F5 epitope-representing NEQELLELDK-
WASLWN peptide [20] (residues 656–671 of gp160). In addi-
tion, ELDKWA and dilysoCL reverted Mab2F5-induced
blockade of syncytium formation (micrographs in panel B).
The interaction of surface expressed gp120/gp41 on eﬀector
cells with target cells expressing CD4 and CXCR4 results in
the fusion of cell membranes and leads to the formation of syn-
cytia. MAb2F5-gp41 binding inhibits the fusion of cell–cell
membrane and syncytium formation (left-hand control (–)
micrograph). Thus, ligand-binding to Mab2F5 resulted in
Mab2F5-gp41 binding inhibition and the recovery of the fu-
sion activity (middle and right-hand micrographs). Quantita-tion of the Mab2F5-gp41 binding inhibition as a function of
the concentration also revealed a comparable potency for
ELDKWA and dilysoCL. Again, the longer linear NEQEL-
LELDKWASLWN peptide displayed the highest interference,
consistently with the notion that it displays a much higher
aﬃnity towards the antibody. In summary, these results sug-
gest that the recognition of core-epitope ELDKWA and of
dilysoCL by Mab2F5 occurs with comparable aﬃnities. In
addition, these data are consistent with the observation that
residues of the epitope located outside the core [20], also con-
tacted by the antibody [14], are important contributors of
Mab2F5-epitope recognition [21].4. Concluding remarks
In principle, two structural elements may sustain PL–
Mab2F5 interactions: the hydrophobic-at-interface CDR loop,
and the epitope-binding pocket (Fig. 4). It is reasonable to ex-
pect that the former would drive unspeciﬁc partitioning into
membrane-interfaces [11,14], while the latter would sustain
more speciﬁc recognition processes, such as those described
to occur by Haynes at al. [12]. Our results support non-speciﬁc
binding to negatively charged and electrically neutral inter-
faces (left-hand panel in Fig. 4) that might occur through the
Fig. 3. Mab2F5 aﬃnity for soluble phospholipid and peptide ligands.
(A) Inhibition of Mab2F5 binding to MPER immobilized in plaques
by pre-incubation in solution with dilysoCL (circles), core-epitope
ELDKWA (squares) and long linear epitope NEQELLELDK-
WASLWN (triangles). MPER and Mab2F5 were used in ELISA
assays at the concentrations of 5 and 0.1 lg/ml, respectively. (B)
Fusion activity recovery by pre-incubation with peptides. Top: Cells
grown in 96-well plates were treated with Mab2F5 (5 lg/well)
alone (left-hand micrograph) or pre-incubated with 50 lM of either
ELDKWA (center) or dilysoCL (right-hand micrograph). Bottom:
Inhibition of Mab2F5 (5 lg/well) blockade of syncytium formation by
pre-incubation with dilysoCL (circles), ELDKWA (squares) and
NEQELLELDKWASLWN (triangles). Complete inhibition value
was set to the number of nuclei present in syncytial plaques (fused
cells containing 4 or more nuclei) per ﬁeld, in the absence of Mab2F5.
Means of duplicate points in representative experiments are displayed
in A–B (bottom) plots. Dashed lines have been included for better
comparison and represent ﬁttings of the NEQELLELDKWASLWN
values to saturation curves.
Fig. 4. Diﬀerent mechanisms of PL recognition at membrane-interface
by Mab2F5. Association with PC or PG bilayer interfaces (left-hand
panel) is driven through non-speciﬁc partitioning of the hydrophobic-
at-interface loop (blue toe). By comparison, association with CL
bilayers (right-hand panel) results from loop-membrane partitioning
plus occupancy of the epitope-binding pocket (green area). For clarity
only the 2F5 antigen-binding fragment has been represented.
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contrast CL seems to occupy the epitope-binding pocket
(right-hand panel in Fig. 4).
A unique property of CL is its propensity to speciﬁcally
interact with a variety of unrelated proteins, among others
diﬀerent components of the respiratory chain, as well as key
components of the apoptotic cascade such as BAX and cBID
[22–24]. Importantly, although the underlying molecular
mechanism is not well understood, cBID has been shown to
interact speciﬁcally not only with CL-containing lipid bilayers,
but also with its soluble lyso-derivatives [24]. Our data supportthe existence of a similar CL-binding mechanism for HIV-1
neutralizing Mab2F5 and, therefore, provide molecular
grounds for the suggestion that conserved MPER epitopes
constitute mimics of autoantibody epitopes [12].
Finally, it should be noted that neutralizing antibodies have
been reported in autoimmune HIV-1 negative patients [25],
and anticardiolipin antibodies have been detected in patients
with various virus infections including HIV-1 [26]. The anti-
body 2F5 was developed in a HIV-infected individual, but
there is no available information on the presence of autoim-
mune antibodies in this patient. Thus, it remains unknown
whether Mab2F5 was originally developed in the HIV-infected
individual in response to the ELDKWA sequence of gp41 or
cardiolipin.
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